Literature DB >> 21458090

Commissioning of volumetric modulated arc therapy (VMAT) in a dual-vendor environment.

Barbara Dobler1, Christian Groeger, Marius Treutwein, Judith Alvarez-Moret, Thomas Goetzfried, Karin Weidner, Petra Haertl, Oliver Koelbl.   

Abstract

Methods and results for commissioning of the complete VMAT delivery chain are presented for the combination of Nucletron's Oncentra MasterPlan® v3.3 with Elekta's Mosaiq® v1.6 and SynergyS® linac. VMAT specific linac commissioning included determination of the size of the minimal dynamic leaf gap. Dosimetric validation of the complete treatment chain was performed using a 2D-ionization-chamber-array and showed excellent dosimetric results.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Mesh：

Year:  2011        PMID： 21458090     DOI： 10.1016/j.radonc.2011.01.024

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN： 0167-8140            Impact factor:   6.280


  10 in total

1.  Minimum requirements for commissioning and long-term quality assurance of Elekta multi-leaf collimator for volumetric modulated arc therapy.

Authors:  Daisaku Tatsumi; Ryosei Nakada; Akane Yomoda; Kentaro Ishii; Shinichi Tsutsumi; Makoto Inoue; Takao Ichida; Masako N Hosono; Yukio Miki
Journal:  Radiol Phys Technol       Date:  2012-08-14

2.  Second Cancer Risk after simultaneous integrated boost radiation therapy of right sided breast cancer with and without flattening filter.

Authors:  Barbara Dobler; Johannes Maier; Bernadette Knott; Manuel Maerz; Rainer Loeschel; Oliver Koelbl
Journal:  Strahlenther Onkol       Date:  2016-08-17       Impact factor: 3.621

3.  Searching standard parameters for volumetric modulated arc therapy (VMAT) of prostate cancer.

Authors:  Marius Treutwein; Matthias Hipp; Oliver Koelbl; Barbara Dobler
Journal:  Radiat Oncol       Date:  2012-07-11       Impact factor: 3.481

4.  Report on use of a methodology for commissioning and quality assurance of a VMAT system.

Authors:  Charles Mayo; Luis Fong de los Santos; Jon Kruse; Charles R Blackwell; Luke B McLemore; Deanna Pafundi; Joshua Stoker; Michael Herman
Journal:  PLoS One       Date:  2013-03-15       Impact factor: 3.240

5.  Three-dimensional radiochromic film dosimetry for volumetric modulated arc therapy using a spiral water phantom.

Authors:  Masao Tanooka; Hiroshi Doi; Hideharu Miura; Hiroyuki Inoue; Yasue Niwa; Yasuhiro Takada; Masayuki Fujiwara; Toshiyuki Sakai; Kiyoshi Sakamoto; Norihiko Kamikonya; Shozo Hirota
Journal:  J Radiat Res       Date:  2013-05-17       Impact factor: 2.724

6.  Simultaneous integrated boost (SIB) radiation therapy of right sided breast cancer with and without flattening filter - A treatment planning study.

Authors:  Johannes Maier; Bernadette Knott; Manuel Maerz; Rainer Loeschel; Oliver Koelbl; Barbara Dobler
Journal:  Radiat Oncol       Date:  2016-08-31       Impact factor: 3.481

7.  Re-irradiating spinal column metastases using IMRT and VMAT with and without flattening filter - a treatment planning study.

Authors:  Barbara Dobler; Amine Khemissi; Tina Obermeier; Matthias G Hautmann; Zaira Katsilieri; Oliver Kölbl
Journal:  Radiat Oncol       Date:  2016-03-01       Impact factor: 3.481

8.  IMRT and RapidArc commissioning of a TrueBeam linear accelerator using TG-119 protocol cases.

Authors:  Ning Wen; Bo Zhao; Jinkoo Kim; Karen Chin-Snyder; Maria Bellon; Carri Glide-Hurst; Kenneth Barton; Daiquan Chen; Indrin J Chetty
Journal:  J Appl Clin Med Phys       Date:  2014-09-08       Impact factor: 2.102

9.  Volumetric-modulated arc therapy and intensity-modulated radiation therapy treatment planning for prostate cancer with flattened beam and flattening filter free linear accelerators.

Authors:  Marius Treutwein; Matthias Hipp; Oliver Koelbl; Barbara Dobler
Journal:  J Appl Clin Med Phys       Date:  2017-08-30       Impact factor: 2.102

10.  Secondary malignancy risk for patients with localized prostate cancer after intensity-modulated radiotherapy with and without flattening filter.

Authors:  Marius Treutwein; Rainer Loeschel; Matthias Hipp; Oliver Koelbl; Barbara Dobler
Journal:  J Appl Clin Med Phys       Date:  2020-11-04       Impact factor: 2.102
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.